ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months
2023年8月17日 - 4:00AM
ビジネスワイヤ(英語)
ZWorldwide Commits to Minimum Annual Volume
Purchases for Five Years
ZIVO’s Partner Alimenta Expects to Have
Significantly Expanded Production Capacity Fully Operational in
2025 to Meet Projected Demand
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the
“Company”), a biotech/agtech R&D company engaged in the
development of therapeutic, medicinal and nutritional product
candidates derived from proprietary algal cultures, today provided
an update on the commercialization of Zivolife, its proprietary
algal biomass as a food or food ingredient.
Following strong initial sales, ZWorldwide, an independent
distributor with exclusive rights to the Zivolife product in North
America, informed ZIVO that as part of its commercial agreement it
will purchase the entire supply of Zivolife produced for the first
18 months. Additionally, subject to certain contingencies, for each
of the next five years including the commitment for the initial
18-month period, ZWorldwide has committed to purchasing at least
24,000 kilograms of product.
“With the successful introduction of Zivolife to the green
powder market and sales agreements locked in, we are now actively
working with ZWorldwide to drive commercial success and with our
contract cultivation partner, Alimenta Algae, to increase
production volumes. ZIVO has the know-how to cultivate our
proprietary algal biomass in far greater volumes, and we are
pursuing plans to increase capacity as rapidly as possible,” said
John Payne, CEO and Chairman of ZIVO Bioscience.
ZIVO is collaborating with Alimenta Algae SAC (“Alimenta Algae”)
to repurpose their prior microalgae facility into a larger and more
efficient cultivation and processing facility that, once completed,
is expected to have the ability to produce up to 100,000 kilograms
of dried product per year. The new facility is anticipated to be
fully operational in the second or third quarter of 2025. Under the
terms of its supply agreement, Alimenta has committed to ZIVO that
it will make the necessary investments to the cultivation ponds and
to downstream processing. Alimenta Algae is the microalgae
subsidiary of Grupo Alimenta, a global, multi-generational,
family-run agribusiness with headquarters in Lima, Peru.
“With the key elements of a commercial strategy in place, we now
have a manufacturing plan that is capable of meeting the demand
we’re projecting for Zivolife in this initial market entry. I am
optimistic about the future of ZIVO and the consumer uptake of our
algal biomass product. Increasing production volume, our primary
focus, is a direct path to increasing sales, and we are delighted
to announce the significant upgrades Alimenta will be making to
their aquaculture facility,” added Mr. Payne.
Zivolife is natural, non-GMO and a high source of plant-based
protein, naturally occurring beta glucan and fiber. ZIVO’s dried
microalgae is a source of essential amino acids, polyphenols, iron,
potassium and vitamins A, E and B12. Zivolife supports digestive
and gut health and helps to support a healthy immune system. It has
a mild taste compared with other microalgae and has been tested as
shelf stable for up to two years. Zivolife is 100% made from ZIVO’s
proprietary microalgae. For more information about ZWorldwide and
Zivolife, please visit www.zivo.life.
Zivolife is cultivated at a single-source, sustainable
aquaculture facility in the foothills of the Peruvian Andes
Mountains using proprietary cultivation processes developed in
partnership with ZIVO. The partnership has established
quality-control testing at facilities in Ica, Peru, Ft. Myers,
Florida and certified third-party laboratories. Zivolife will
initially be available in limited quantities as ZIVO scales up
production. For more information about Grupo Alimenta, please visit
www.alimenta.pe.
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an
intellectual property portfolio comprised of proprietary algal and
bacterial strains, biologically active molecules and complexes,
production techniques, cultivation techniques and patented or
patent pending inventions for applications in human and animal
health. Please visit www.zivobioscience.com for more
information.
Forward Looking Statements
Except for any historical information, the matters discussed in
this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Although ZIVO believes
that we have a reasonable basis for each forward-looking statement,
we caution you that these statements are based on a combination of
facts and factors currently known by us and our expectations of the
future, about which we cannot be certain. Our actual future results
may be materially different from what we expect due to factors
largely outside our control, including risks that our strategic
partnerships may not facilitate the commercialization or market
acceptance of our products; risks that we will be unable to
increase production sufficient to meet our expected demand; risks
that our products may not be ready for commercialization in a
timely manner or at all; risks that our products will not perform
as expected based on results of our pre-clinical and clinical
trials; our ability to raise additional funds; uncertainties
inherent in the development process of our products; changes in
regulatory requirements or decisions of regulatory authorities; the
size and growth potential of the markets for our products; the
results of clinical trials, our ability to protect our intellectual
property rights and other risks, uncertainties and assumptions,
including those described under the heading “Risk Factors” in our
filings with the Securities and Exchange Commission. These
forward–looking statements speak only as of the date of this press
release and ZIVO undertakes no obligation to revise or update any
forward–looking statements for any reason, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230816682913/en/
ZIVO Bioscience Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130 kmarchiando@zivobioscience.com LHA Investor
Relations Tirth T. Patel (212) 201-6614 tpatel@lhai.com
Zivo Bioscience (NASDAQ:ZIVO)
過去 株価チャート
から 4 2024 まで 5 2024
Zivo Bioscience (NASDAQ:ZIVO)
過去 株価チャート
から 5 2023 まで 5 2024